Drugs / Pvs230D1-EPA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05913973 | Aug 2023 → Nov 2025 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pvs230D1-EPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05913973 ↗ |
| Modality | Protein / enzyme biologic | “Pvs230 domain 1 (Pvs230D1) is a recombinant protein consisting of subdomain 1 of native Pvs230 (Val-226 to Gly-427, Figure 2) produced in Pichia pastoris.” NCT05913973 ↗ |
| Route | Intramuscular | “The vaccine will be injected into the muscle of the upper arm.” NCT05913973 ↗ |